Kornimate/medical-research-clean huggingface dataset:
hiv prevention preparedness study in russia, china, and india

Conditions: HIV Infections

Summary: the purpose of this study is to set up a system for doing research on hiv prevention in various parts of the world. in order to plan large, long-term studies on the prevention of hiv in different areas of the world, it is necessary to get certain information first. it is important to know about the rate of hiv infection and how to get people to enroll for any future studies. this study will be done at 4 study locations.

in order to realistically plan for future phase iii studies on hiv prevention, information must be obtained to characterize study population parameters at htpn sites. very different study designs may be required depending on these parameters, such as the ability of hptn research centers to recruit study participants and the rate of hiv incidence observed in study populations. this study will be conducted at 4 hptn sites to establish the necessary research knowledge and infrastructure. this study enrolls participants from st. petersburg, russia; xinjiang and guangxi, china; and chennai, india who are at high risk for hiv infection due to sexual and/or drug use behaviors. participants who meet the screening criteria then complete an hiv risk assessment interview, receive hiv pre-test and risk reduction counseling, and undergo phlebotomy for hiv antibody testing. participants who test positive are referred to available services and studies. those who test hiv-negative and meet eligibility criteria are enrolled and maintained in follow-up over the next 12 months. participants complete "locator contacts" at months 3 and 9 and have follow-up visits at months 6 and 12 for similar tests as performed at entry. in a substudy of this trial in china, participants will be interviewed about their drug use, social networks, needs, and perceptions about hiv/aids. these results will be used by hptn to design more culturally sensitive and appropriate trials in the future.

Eligibility criteria:
inclusion criteria participants may be eligible for this study if they: * are 16 (saint petersburg) or 18 (xinjiang, guangxi, and chennai) years of age or older. * are hiv sero-negative. * are available for 12 months of study participation. * have written consent of parent or legal guardian if under age. * are able and willing to provide information on where they can be located or contacted. * meet specific risk-group requirements, for women at heterosexual risk, for men at heterosexual risk, and for injection drug users. exclusion criteria participants will not be eligible for this study if they: * have any mental disorders that would cause a problem with the informed consent or study participation. * have any condition that, in the opinion of the doctor, would interfere with the study.

Keywords: risk factors incidence patient selection hiv seronegativity
spirocor coronary outcome by respiratory stress examination

Conditions: Severe Coronary Artery Disease (S-CAD)

Summary: the purpose of this study is to validate the accuracy of the spirocor system in indicating the presence of significant coronary artery disease (s-cad), as defined in acc/aha guidelines, in subjects with suspected s-cad.


Eligibility criteria:
inclusion criteria: * subject with suspected s-cad * subject able to perform the guided breathing protocol and comply with study requirements * subject is able and agrees to sign the informed consent form exclusion criteria: * resting (supine) ecg evidence of st-segment depression ≥ 1 mm in any lead or left bundle branch block or significant arrhythmia * current digoxin therapy * subject has severe valvular heart disease * subject has congestive heart failure nyha class iii/iv * subject has known history of myocardial infarction (st elevation or non st elevation) * subject had previous coronary revascularization: cabg or pci * subject has pacemaker or icd that controls sinus * morbidly obese subject (bmi ≥ 40) * subject has any significant medical condition which, at the investigator's discretion, may interfere with the subject's optimal participation in the study; and * subject is currently participating in another investigational product clinical study that the investigator believes may interfere with the outcome of this study

Keywords: rsr secg spect qca scad
influences of high-fiber, organic whole-food formula on the gut microbiome in critically ill children

Conditions: Critical Illness; Dysbiosis; Pediatric ALL

Summary: this study evaluates the effects of either pediasure or nourish formulas on the gastrointestinal microbiome in critically-ill children. patients will be randomized to received either pediasure or nourish.

the gastrointestinal microbiome has been shown to be altered in critically-ill children such that there is a larger shift toward pathogenic bacteria. previous studies have shown that probiotics, fecal transplants, antibiotic decontamination, and dietary interventions can shift the gastrointestinal microbiome toward a metabolically favorable microbiome profile and be associated with improvements in disease burden. this study will randomize critically-ill children who are stable enough for enteral tube feedings to receive either pediasure or nourish. pediasure is a commercially-made formula that is used commonly in pediatric patients. nourish is an organic, whole-food formula with a high fiber content. high-fiber diets have been correlated with metabolically favorable microbiome profiles. this study will look at the microbiome before and after initiation of enteral tube feedings to determine if either formula is associated with a shift in the microbiome toward a favorable profile.

Eligibility criteria:
inclusion criteria: * admitted to the pediatric intensive care unit * age 1-17 years old * previously placed enteric tube designed for enteric feeding exclusion criteria: * vasoactive medication use * history of allergies or intolerances to either pediasure or nourish * whey allergy or intolerance * gluten sensitivity or intolerance * medical condition that necessitate the use of specific formulas and/or nutritional needs (e.g. epilepsy requiring ketogenic diet, genetic metabolic dysfunction with specific formula requirements)

Keywords: microbiome gastrointestinal microbiome pediatrics critical illness
biomarkers and neurological outcome in neonates 2

Conditions: Asphyxia Neonatorum

Summary: follow-up of participants of banon1 study at age of at least 2 years. banon1 (clinicaltrials.gov id: nct03357250): validation of biomarkers based on 24 months neuro-developmental outcome data in a human population for their ability to diagnose the severity of neonatal asphyxia. these biomarkers linked to asphyxia have been identified in animal studies and a preliminary human study.

follow-up on neuro-developmental status of study participants of banon1. banon1 (clinicaltrials.gov id: nct03357250): the aim of the study is to validate the application of combinations of several laboratory parameters in early postnatal blood samples, for identification of infants, who will suffer from early abnormal neonatal neurological outcome, in a population at risk. the population at risk is defined as term and late preterm (\>36 weeks of gestation) human infants following perinatal hypoxia-ischemia with or without postnatal resuscitation, and where the combination of laboratory parameters is derived from a preliminary study performed in turkey (aambi) using a metabolomics approach.

Eligibility criteria:
inclusion criteria: * infants previously enrolled in banon study exclusion criteria: * missing valid written informed parental consent

Keywords: biomarkers asphyxia hypoxic ischemic encephalopathy
assessment of renal function by multiparametric mri

Conditions: Renal Impairment

Summary: metabolic syndrome is a collection of conditions that affect at least three of the following five criteria: abdominal obesity, high blood pressure, high fasting glucose levels, high triglyceride levels, and low levels of high-density lipoprotein (hdl) cholesterol. chronic kidney disease (ckd) is a common complication of metabolic syndrome, with an estimated prevalence of 13-40%. early diagnosis of progressive conditions before the onset of reduced glomerular filtration rate (gfr) or albuminuria may be of clinical benefit but is not possible at present. furthermore, the diagnosis and quantification of ckd in the context of metabolic syndrome is challenging due to the lack of reliable diagnostic biomarkers, and the current methods may not accurately reflect kidney function in patients with metabolic syndrome. magnetic resonance imaging (mri) has been sparsely explored as a potential tool to assess renal perfusion, oxygenation, and fibrosis. multiparametric mri (mpmri) combines several different imaging techniques to provide a more comprehensive evaluation of tissue structure and function. these techniques hold promise for non-invasive assessment of kidney function, but their clinical utility is still largely experimental. therefore, we aim to conduct an exploratory study to investigate the reliability, reproducibility as well as the validity of parameters for kidney function of multiparametric mri as well as compare these parameters in between healthy patients and patients with metabolic syndrome.


Eligibility criteria:
inclusion criteria: * diagnosed metabolic syndrome exclusion criteria: * mri exclusion criteria
which position is better for cpr in ohca patients?

Conditions: Cardiac Arrest (CA)

Summary: use transesophageal ultrasound in ohca patients to identify the proper cpr position


Eligibility criteria:
inclusion criteria: * out of hospital cardiac arrest patients exclusion criteria: * dnr was signed, * age under 18 * trauma patients * patients hard to establish advanced airway * c spine injury patients

Keywords: ohca tee
observational and prospective study of hepatic steatosis and related risk factors using ultrasound and artificial intelligence

Conditions: Liver Steatoses

Summary: fatty liver is the most frequent chronic liver disease worldwide and ultrasonography is widely employed for diagnosis. the accuracy of this technique, however, is strongly operator-dependent. few information is available, so far, on the possible use of algorithms based on artificial intelligence (ai) to ameliorate the diagnostic accuracy of ultrasonography in diagnosing fatty liver. this study showed that the use of ai is able to improve the diagnostic accuracy of ultrasonography in the diagnosis of fatty liver

in recent years, ultrasound has taken on a predominant role in the evaluation of liver steatosis, as it is a non-invasive, non-irradiating method that is easily reproducible and inexpensive. of particular effectiveness is the use of the hepatorenal index, evaluated as the intensity ratio (echogenicity) between the hepatic parenchyma and the renal cortical parenchyma. the main limitations of detecting the hepato-renal index during abdominal ultrasound, however, are operator dependence and the use of a relatively long time span to complete the sequence of operations and calculations required to determine the index itself. the use of artificial intelligence (ai) techniques for image analysis in the medical field is yielding excellent results. ai-based algorithms are increasingly a powerful tool that allows the physician to improve their performance in terms of speed and accuracy of clinical evaluations. today, there is already evidence of the effectiveness of using ai on ultrasound images for clinical evaluations. the use of ai as an aid in diagnosing liver diseases through ultrasound is still under-researched. the hypothesis to be tested is the utility that ai can have in the evaluation, its general and specific uses in reducing calculation times of the hepatorenal index. in this study, 134 patients were enrolled with no clinical suspicion of liver steatosis. all patients underwent abdominal ultrasonography (us) and magnetic resonance imaging fat fraction (mri-pdff), assumed as reference technique to evaluate the grade of steatosis. the hepatorenal index (us) was manually calculated (hrim) by 4 skilled operators. an automatic hepatorenal index calculation (hria) was also obtained by an algorithm. the accuracy of hria to discriminate different grades of fatty liver was evaluated by receiver operating characteristic (roc) analysis using mri-pdff cut-offs.

Eligibility criteria:
inclusion criteria: * age between 18-70 years * mri regardless of clinical indications, * written informed consent exclusion criteria: * cirrhosis * hepatocellular carcinoma or any liver tumours, * absence of the right kidney * previous liver transplantation * large liver cysts or kidney cysts
effect of phenazopyridine on prolapse surgery voiding trials

Conditions: Urinary Retention Postoperative

Summary: to determine if phenazopyridine reduces the rate of postoperative urinary retention after pelvic organ prolapse surgery.

several tools can be used to evaluate for ureteral patency during urogynecologic procedures. typically, surgeons use urine dyes such as methylene blue, indigotindisulfonate sodium, or phenazopyridine, with the latter being restricted to oral administration. however in june 2014, the two u.s. manufacturers of indigotindisulfonate sodium stopped producing the medication and there is no prospect that it will be returning soon. phenazopyridine is an over-the-counter medication (azo-gesic, baridium, urinary pain relief) that has been used safely for decades as a bladder analgesic and taints the urine orange. over the past few months, increasing evidence suggests that phenazopyridine may reduce transient postoperative urinary retention. transient urinary retention is common after urogynecologic surgery and is assessed postoperatively by performing a void trial (vt) prior to discharge. in a study designed to determine the time from administration of oral phenazopyridine to visualize dye from the ureters, propst et al incidentally found that 38% of patients (19 of 49) failed postoperative vts without phenazopyridine, but only 19% (9 of 47) failed with phenazopyridine, p=0.04. most recently, a study by duenas-garcia et al designed to examine local anesthetics and urinary retention in subjects undergoing midurethral slings found that phenazopyridine decreased the vt failure rate from 30% to 8% (5). the investigators hypothesize that giving a dose of phenazopyridine the morning after surgery will significantly reduce the rate of postoperative urinary retention in women undergoing prolapse repair.

Eligibility criteria:
inclusion criteria: * women undergoing overnight admission after prolapse surgery exclusion criteria: * unable to provide consent * under 18 years of age * pregnant women * prisoners * using intermittent self-catheterization preoperatively * neurological disease or spinal cord injury resulting in voiding dysfunction * undergoing spinal or epidural anesthesia for the procedure * allergy to phenazopyridine * renal insufficiency * liver disease * intra-operative bladder injury necessitating use of prolonged indwelling foley catheter
efficacy of acupuncture at acupoints group around the base of skull for post-stroke depression

Conditions: Post-stroke Depression

Summary: the objective of this trial is to evaluate the efficacy and safety of electroacupuncture at acupoints group around the base of skull for post-stroke depression.

98 eligible participants with post-stroke depression will be recruited and randomly assigned to the experimental group and the control group in a ratio of 1:1. participants in both groups will receive electroacupuncture or placebo acupuncture treatment at acupoints group around the base of skull 3 times a week for 4 weeks, and followed up for 24 weeks.

Eligibility criteria:
inclusion criteria: 1. conforming to the criteria for the diagnosis of psd recommended by the "chinese expert consensus on clinical practice of post-stroke depression"; 2. aged 40 to 80 years old; 3. the score of hdrs-24 item scale is more than 8 points and less than 35 points, that is, mild to moderate depression; 4. has not received antidepressant treatment or has been discontinued for more than 2 weeks before entering treatment, and has not participated in other ongoing clinical trials. exclusion criteria: 1. subjects with history of mental illness or family history of mental illness; 2. subjects with severe heart, liver, kidney, hematopoietic system, endocrine and immune system diseases; 3. subjects with dementia, aphasia, cognitive dysfunction or unable to cooperate with examination and treatment; 4. subjects installed with the cardiac pacemaker; 5. pregnant or lactating patients.
transition preparation intervention for young adults with type 1 diabetes

Conditions: Type 1 Diabetes

Summary: the purpose of this research study is to find out more about how to support young adults (ages 18-22) with type 1 diabetes as they prepare to transition from pediatric and adult endocrinology medical care.

the overarching goal of the proposed trial is to improve diabetes self-management and glycemic control in young adults and prepare them for the transition to adult endocrinology. the current application will investigate the impact of a multisystem transition preparation intervention for young adults (ages 18-22) with t1d. twenty-five young adults and a parent will be enrolled in a 6-month transition preparation program which will use a hybrid in-person and technology delivery structure. providers will receive training highlighting their role preparing young adults for transition and provides practical tips to use in their communication with young adults. if effective, this multisystem intervention, designed to enhance t1d self-management and increase young adults' readiness for transition to adult healthcare during this critical developmental period, has the potential to inform clinical practice guidelines.

Eligibility criteria:
inclusion criteria: both members of the youth/parent dyad must meet all eligibility criteria young adults * english-speaking * patients in pediatric endocrinology at children's hospital of richmond (chor) at virginia commonwealth university (vcu) * between ages 18-22 yrs with a * diagnosis of t1d for \>1 year parents * greater than 18 years of age * provide care to the young adult with t1d * are willing to participate in the intervention medical providers • provide care to patients with t1d ages 18-22 yrs in pediatric endocrinology at chor exclusion criteria: young adults * significant psychiatric, cognitive, medical or developmental conditions that would impair their ability to complete assessments and/or engage in diabetes self-care behaviors (e.g., malignancies, psychosis, intellectual disability), as documented in the medical record or revealed during eligibility screening, or * medically-induced diabetes or diagnosis of diabetes other than type 1 diabetes parents * non-english speaking * psychiatric, cognitive, or developmental conditions that would impair their ability to complete assessments and/or engage in the intervention as determined at study screening

Keywords: transition young adult
effects of sedante neo therapy on pain, range of motion and quality of life in patients with non specific low back pain.

Conditions: Low Back Pain; Range of Motion; Pain

Summary: this study is to evaluate the effects of sadante neo therapy on pain, range of motion and quality of life in patients with non-specific low back pain.

this study is to evaluate sadante neo therapy on pain, range of motion and quality of life in patients with low back pain. this study will identify the effects that will help the physiotherapists in making the treatment plan for low back pain. this can be an alternative non pharmacological therapy to improve the quality of pain management with maximum benefits and minimal side effects.

Eligibility criteria:
inclusion criteria: * age group of 20 yeras to 40 years. * both male and female included. * having non-specific low back pain. * having sf-mpq score 1and 2 (1 means mild, 2 means moderate) * having odi score 5 to 24 * having sf-36 healty survey score below 50 * having range of motion below normal. exclusion criteria: * below 20 years and above 40 years patient are excluded * cervical, knee pain and other conditions excluded. * children are excluded * red flags ( tuberculosis, carcinoma heart disease etc) excluded -open sores * psychiatric diseases such as depression, phobias * patient with history of surgery in lumber region

Keywords: sedante neo therapy non specific low back pain quality of life
a comparison of two types of injected nutritional supplements in patients with aids and pneumocystis carinii pneumonia (pcp)

Conditions: HIV Infections

Summary: the objectives of this study are: to establish whether there is a difference in clinical effectiveness of liposyn ii 20 percent as compared with liposyn iii 2 percent in aids patients with pneumocystis carinii pneumonia (pcp). to compare the effects of the two lipid emulsions on immunologic function in aids patients. to compare the effect of the two lipid emulsions on hiv load in aids patients as measured by reverse transcriptase (rt) in culture. to determine whether a decrease in hiv infectivity is greater in patients given a parenteral feeding regimen containing liposyn ii 20 percent or liposyn iii 2 percent.


Eligibility criteria:
inclusion criteria concurrent medication: allowed: * all drugs used for the standard treatment of pneumocystis carinii pneumonia (pcp). * other drugs for treatment of other aids conditions if they have been started more than 3 months prior to study entry. patients must have: * diagnosis of aids. * weight loss \> 10 percent of premorbid body weight. * first or second episode of acute pneumocystis carinii pneumonia (pcp). exclusion criteria co-existing condition: patients with the following conditions or symptoms are excluded: * do not resuscitate (dnr) status. * biliary stasis. patients with the following are excluded: * do not resuscitate (dnr) status. * biliary stasis. prior medication: excluded within 3 months of study entry: * immunomodulators. * antiviral new dt

Keywords: weight loss pneumonia, pneumocystis carinii parenteral nutrition liposyn acquired immunodeficiency syndrome
evaluation of the efficacy, tolerability, and patient acceptance of dermatix q for the prevention and management of scars

Conditions: Scars

Summary: the purpose of this study is to evaluate the efficacy and patient acceptance of dermatix q for the prevention and treatment of scarring.


Eligibility criteria:
inclusion criteria: * female or male patients at least 18 years of age * patients who are at serious risk of hypertrophic scarring (due to family history, race, recent surgery, etc) * able and willing to provide informed consent and likely to complete all study visits * all fitzpatrick skin types will be evaluated exclusion criteria: * known contraindications to dermatix or any of its components * age of scar is \> 4 months * keloid scars (scars with increased fibroblastic activity that has exceeded the boundaries of the original scar)